{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:58:13Z","timestamp":1790470693763,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.coviro.2019.07.006","type":"journal-article","created":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T18:06:14Z","timestamp":1567015574000},"page":"105-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["A review of Lassa fever vaccine candidates"],"prefix":"10.1016","volume":"37","author":[{"given":"Kolawole","family":"Salami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Gouglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Schmaljohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Saville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Tornieporth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2019.07.006_bib0005","doi-asserted-by":"crossref","first-page":"670","DOI":"10.4269\/ajtmh.1970.19.670","article-title":"Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings","volume":"19","author":"Frame","year":"1970","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.coviro.2019.07.006_bib0010","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jcv.2014.12.004","article-title":"Research efforts to control highly pathogenic arenaviruses: a summary of the progress and gaps","volume":"64","author":"Kerber","year":"2015","journal-title":"J Clin Virol"},{"key":"10.1016\/j.coviro.2019.07.006_bib0015","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1016\/j.vaccine.2017.06.003","article-title":"The complexity and cost of vaccine manufacturing \u2013 an overview","volume":"35","author":"Plotkin","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2019.07.006_bib0020","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-018-0049-5","article-title":"Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development review-article","volume":"3","author":"Hallam","year":"2018","journal-title":"npj Vaccines"},{"key":"10.1016\/j.coviro.2019.07.006_bib0025","series-title":"Priority diseases \u2013 CEPI","author":"Coalition for Epidemic Preparedness Innovations","year":"2018"},{"key":"10.1016\/j.coviro.2019.07.006_bib0030","series-title":"WHO Target Product Profile for Lassa virus Vaccine","author":"World Health Organization","year":"2017"},{"key":"10.1016\/j.coviro.2019.07.006_bib0035","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1080\/14760584.2016.1184575","article-title":"Vaccine platforms to control Lassa fever","volume":"15","author":"Lukashevich","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.coviro.2019.07.006_bib0040","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(15)61117-5","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial","volume":"386","author":"Henao-Restrepo","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2019.07.006_bib0045","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1080\/21645515.2017.1356500","article-title":"A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever","volume":"13","author":"Cashman","year":"2017","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.coviro.2019.07.006_bib0050","unstructured":"Inovio Pharmaceuticals: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers \u2013 Full Text View \u2013 ClinicalTrials.gov. 2019."},{"key":"10.1016\/j.coviro.2019.07.006_bib0055","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.3390\/v4112514","article-title":"Advanced vaccine candidates for Lassa fever","volume":"4","author":"Lukashevich","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2019.07.006_bib0060","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1016\/j.vaccine.2007.02.038","article-title":"A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity","volume":"25","author":"Carrion","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2019.07.006_bib0065","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.3390\/v4112514","article-title":"Advanced vaccine candidates for Lassa fever","volume":"4","author":"Lukashevich","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2019.07.006_bib0070","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1743-422X-10-52","article-title":"An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity","volume":"10","author":"Zapata","year":"2013","journal-title":"Virol J"},{"key":"10.1016\/j.coviro.2019.07.006_bib0075","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1743-422X-10-52","article-title":"An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity","volume":"10","author":"Zapata","year":"2013","journal-title":"Virol J"},{"key":"10.1016\/j.coviro.2019.07.006_bib0080","doi-asserted-by":"crossref","first-page":"e1386","DOI":"10.1016\/S2214-109X(18)30346-2","article-title":"Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study","volume":"6","author":"Gouglas","year":"2018","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.coviro.2019.07.006_bib0085","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1080\/21645515.2017.1383575","article-title":"Chimpanzee adenoviral vectors as vaccines for outbreak pathogens","volume":"13","author":"Ewer","year":"2017","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.coviro.2019.07.006_bib0090","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/1743-422X-7-306","article-title":"Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever","volume":"7","author":"Branco","year":"2010","journal-title":"Virol J"},{"key":"10.1016\/j.coviro.2019.07.006_bib0095","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.2147\/DDDT.S147276","article-title":"Current research for a vaccine against Lassa hemorrhagic fever virus","volume":"12","author":"Warner","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.coviro.2019.07.006_bib0100","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jviromet.2008.10.026","article-title":"Marker gene swapping facilitates recombinant Modified Vaccinia Virus Ankara production by host-range selection","volume":"156","author":"Di Lullo","year":"2009","journal-title":"J Virol Methods"},{"key":"10.1016\/j.coviro.2019.07.006_bib0105","doi-asserted-by":"crossref","first-page":"e1000695","DOI":"10.1371\/journal.ppat.1000695","article-title":"A multivalent and cross-protective vaccine strategy against arenaviruses associated with human disease","volume":"5","author":"Kotturi","year":"2009","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2019.07.006_bib0110","doi-asserted-by":"crossref","first-page":"9947","DOI":"10.1128\/JVI.00672-10","article-title":"A multivalent vaccination strategy for the prevention of old world arenavirus infection in humans","volume":"84","author":"Botten","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2019.07.006_bib0115","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/01.qai.0000513853.86433.29","article-title":"F-105 Vesiculovirus vectored vaccines can provide single dose protection against filoviruses, arenaviruses, and alphaviruses","volume":"74","author":"Fouts","year":"2017","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.coviro.2019.07.006_bib0120","series-title":"IAVI and the Public Health Agency of Canada Enter into License Agreement for Technology to Enable Lassa Fever Vaccine Development \u2013 IAVI \u2013 International AIDS Vaccine Initiative","author":"International Aids Vaccine Initiative","year":"2018"},{"key":"10.1016\/j.coviro.2019.07.006_bib0125","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1128\/JVI.02948-15","article-title":"Animal model of sensorineural hearing loss associated with Lassa virus infection","volume":"90","author":"Yun","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2019.07.006_bib0130","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1038\/s41467-018-06741-w","article-title":"Non-neutralizing antibodies elicited by recombinant Lassa\u2013Rabies vaccine are critical for protection against Lassa fever","volume":"9","author":"Abreu-Mota","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2019.07.006_bib0135","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.virol.2005.12.001","article-title":"A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins","volume":"345","author":"Bredenbeek","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2019.07.006_bib0140","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.virol.2016.11.001","article-title":"Development of live-attenuated arenavirus vaccines based on codon deoptimization of the viral glycoprotein","volume":"501","author":"Cheng","year":"2017","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2019.07.006_bib0145","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.4161\/hv.34413","article-title":"VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever","volume":"10","author":"Leblanc","year":"2014","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.coviro.2019.07.006_bib0150","series-title":"Polyhedrin-encased glycoproteins as novel cold chain independent vaccines","author":"UKRI","year":"2016"},{"key":"10.1016\/j.coviro.2019.07.006_bib0155","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1473-3099(15)70043-5","article-title":"Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial","volume":"15","author":"Ramsauer","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coviro.2019.07.006_bib0160","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02230-17","article-title":"A vaccine platform against arenaviruses based on a recombinant hyperattenuated Mopeia virus expressing heterologous glycoproteins","volume":"92","author":"Carnec","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2019.07.006_bib0165","doi-asserted-by":"crossref","first-page":"11677","DOI":"10.1128\/JVI.75.23.11677-11685.2001","article-title":"Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses","volume":"75","author":"Pushko","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2019.07.006_bib0170","series-title":"Molecular Clamp: a novel protein vaccine for influenza, RSV, Ebola and other viruse","author":"University of Queensland","year":"2016"},{"key":"10.1016\/j.coviro.2019.07.006_bib0175","series-title":"LassaVacc","author":"UK Research and Innovation","year":"2017"},{"key":"10.1016\/j.coviro.2019.07.006_bib0180","doi-asserted-by":"crossref","first-page":"7373","DOI":"10.1128\/JVI.00307-15","article-title":"Arenavirus genome rearrangement for the development of live attenuated vaccines","volume":"89","author":"Cheng","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2019.07.006_bib0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.virol.2016.11.001","article-title":"Development of live-attenuated arenavirus vaccines based on codon deoptimization of the viral glycoprotein","volume":"501","author":"Cheng","year":"2017","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2019.07.006_bib0190","series-title":"Prof. Dr. Ralf Wagner: Trivalent Lassa, Ebola and Marburg viral vaccine (Tri-LEMvac)","year":"2017"},{"key":"10.1016\/j.coviro.2019.07.006_bib0195","series-title":"GeoVax Reports Promising Results for Lassa Fever Vaccine","author":"Geovax","year":"2017"},{"key":"10.1016\/j.coviro.2019.07.006_bib0200","series-title":"Hemorrhagic Fever Vaccine","author":"Geovax","year":"2018"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625719300501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625719300501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:02:44Z","timestamp":1761818564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625719300501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":40,"alternative-id":["S1879625719300501"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2019.07.006","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review of Lassa fever vaccine candidates","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2019.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}